Abstract
Several lines of evidence highlight the importance of a functioning immune system in controlling human papillomavirus (HPV) infection and its associated neoplasms. Harnessing the immune system to both prevent and treat HPV infections has therefore been an area of significant research effort, innovation and progress over the past decades. Although much of the research performed thus far has been on genital HPV infections, the interaction between oral HPV infection and the immune system are beginning to be explored.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932–40.
Bourgault Villada I, Moyal Barracco M, Ziol M, et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 2004;64:8761–6.
Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral oncogenic human papillomavirus (HPV) in men: the HIM cohort study. Lancet. 2013;382:877–87.
D’Souza G, Griffioen AM, Kluz N, et al. Oral HPV prevalence, six-month persistence and incidence among high-risk young adults. In: 28th international papillomavirus conference, San Juan, Puerto Rico; 2012. p. 215.
Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type-16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40:886–91.
Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer. 1999;80:2008–18.
Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212:356–67.
Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86:104–14.
Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res. 1991;51(18 Suppl):5019s–22.
Paternoster DM, Cester M, Resente C, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc. 2008;40:1877–80.
D’Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121:143–50.
Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol. 1996;87:338–44.
Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190:37–45.
Heard I, Tassie JM, Kazatchkine MD, et al. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002;16:1799–802.
Best SR, Peng S, Juang CM, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T-cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.
Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108:669–78.
Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384:410–4.
Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9.
Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001;61:1934–40.
Jochmus-Kudielka I, Schneider A, Braun R, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst. 1989;81:1698–704.
D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:944–56.
Anderson KS, Wong J, D’Souza G, et al. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011;104:1896–905.
Kreimer AR, Johansson M, Waterboer T, et al. An evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. In: 28th international papillomavirus conference 2012; San Juan, Puerto Rico.
Matloubian M, Concepcion RJ, Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056–63.
Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63:636–41.
de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004;64:5449–55.
Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T-lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997;175:927–31.
Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev. 2006;15:1413–4.
Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–65.
Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:S16–22.
Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.
Woodworth CD. HPV innate immunity. Front Biosci. 2002;7:d2058–71.
Ashrafi GH, Haghshenas MR, Marchetti B, et al. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer. 2005;113:276–83.
Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178:3186–97.
Huang SM, McCance DJ. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol. 2002;76:8710–21.
Lee SJ, Cho YS, Cho MC, et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol. 2001;167:497–504.
Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 1999;259:305–13.
Li S, Labrecque S, Gauzzi MC, et al. The human papillomavirus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 1999;18:5727–37.
Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001;75:4283–96.
Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–7.
Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–73.
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.
GlaxoSmithKline. Clinical trial NCT00423046. Cited 2012; Available from: http://clinicaltrials.gov/ct2/show/NCT00423046.
Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11.
Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544–7.
Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years—united states, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–23.
Mullins TL, Zimet GD, Rosenthal SL, et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med. 2012;166:82–8.
Sanders Thompson VL, Arnold LD, Notaro SR. African american parents’ HPV vaccination intent and concerns. J Health Care Poor Underserved. 2012;23:290–301.
Pourat N, Jones JM. Role of insurance, income, and affordability in human papillomavirus accination. Am J Manag Care. 2012;18:320–30.
Bogaards JA, Coupé VM, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22:505–15.
Centers for Disease Control and Prevention (CDC). Genital HPV infection – fact sheet. 2011; Available from: http://www.cdc.gov/std/hpv/stdfact-hpv.htm.
Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol. 2011;29:4294–301.
Cheng WF, Hung CF, Chen CA, et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine. 2005;23:3864–74.
Peng S, Lyford-Pike S, Akpeng B, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother. 2013;62:171–82.
Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838–47.
De Vo svan Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61:1485–92.
Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15:361–7.
Center SKCC. Clinical trial NCT01493154 – safety study of HPV DNA vaccine to treat head and neck cancer patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01493154.
Loddenkemper C, Hoffmann C, Stanke J, et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci. 2009;100:1112–7.
Welters MJ, Kenter GG, de Vo svan Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107:11895–9.
Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27:5911–8.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Carole Fakhry, Gypsyamber D’Souza, Rehan Kazi and Raghav C. Dwivedi
About this chapter
Cite this chapter
Best, S.R., Pai, S.I. (2015). The Role of Vaccines for HPV-Related Head and Neck Cancers. In: Fakhry, C., D’Souza, G. (eds) HPV and Head and Neck Cancers. Head and Neck Cancer Clinics. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2413-6_7
Download citation
DOI: https://doi.org/10.1007/978-81-322-2413-6_7
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2412-9
Online ISBN: 978-81-322-2413-6
eBook Packages: MedicineMedicine (R0)